Health & Fitness
Health and Fitness
Health and Fitness
Fri, July 1, 2011Thu, June 30, 2011Wed, June 29, 2011Tue, June 28, 2011Mon, June 27, 2011Sat, June 25, 2011Fri, June 24, 2011Thu, June 23, 2011Wed, June 22, 2011Tue, June 21, 2011Mon, June 20, 2011Sun, June 19, 2011Fri, June 17, 2011Thu, June 16, 2011Wed, June 15, 2011Tue, June 14, 2011Mon, June 13, 2011Fri, June 10, 2011Thu, June 9, 2011Wed, June 8, 2011Tue, June 7, 2011Mon, June 6, 2011Aethlon Medical to Present at Tomorrow's RedChip Small-Cap Equities Virtual Conference VIII
Published in Health and Fitness on Tuesday, June 21st 2011 at 4:25 GMT by Market Wire
Aethlon Medical to Present at Tomorrow's RedChip Small-Cap Equities Virtual Conference VIII -- SAN DIEGO, June 21, 2011 /PRNewswire/ --
Aethlon Medical to Present at Tomorrow's RedChip Small-Cap Equities Virtual Conference VIII
SAN DIEGO, June 21, 2011 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announces that Chairman and CEO James A. Joyce will present at tomorrow's RedChip Small-Cap Equities Virtual Conference VIII. The live webcast presentation will begin at 10:45 a.m. Pacific time (1:45 p.m. Eastern time) on Wednesday, June 22, 2011, and can be accessed online at: [ http://redchip.com ]
(Photo: [ http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b ])
About Aethlon Medical
The Aethlon Medical mission is to create innovative devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. The Aethlon ADAPT™ system is an expansive technology platform that converges affinity drug agents and plasma membrane technology to create therapeutic filtration devices that selectively target the removal of harmful particles from the entire circulatory system. Our lead therapeutic candidate is the Aethlon Hemopurifier®, a device with broad-spectrum capabilities against viral pathogens and immunosuppressive cancer exosomes. In human studies, Hemopurifier® therapy has provided significant viral load reductions in HIV and hepatitis C virus infected individuals without the administration of antiviral drugs. We are now focused on advancing our Hemopurifier® as an adjunct strategy to improve the benefit of established infectious disease and cancer treatment regimens. Based on studies conducted by government and non-government research organizations, the Hemopurifier® is also a leading broad-spectrum treatment candidate to address bioterror and pandemic threats. For more information, please visit [ www.aethlonmedical.com ].
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
[ jj@aethlonmedical.com ]
Jody Cain
Senior Vice President, Lippert/Heilshorn & Associates
310.691.7100
[ jcain@lhai.com ]
Jim Frakes
Chief Financial Officer
858.459.7800 x300
[ jfrakes@aethlonmedical.com ]
John P. Salvador
Director, Communications & Investor Relations
858.459.7800 x307
[ jps@aethlonmedical.com ]
SOURCE Aethlon Medical, Inc.
[ Back to top ] RELATED LINKS
[ http://www.aethlonmedical.com ]
